Accessing surgical care is of profound significance that face remote African communities due to insufficient healthcare means and infrastructure. Deploying mobile surgical units (MSUs) have present a potential solution to underserved populations in rural Africa to address said issues. The aim of this narrative review is to examine the role of MSU utilization in remote African communities to meet surgical needs and evaluate how this has affected healthcare provision. To identify studies focusing on the dissemination of MSUs in remote African communities covered countries such as Uganda, Kenya, Tanzania, Nigeria, and Ethiopia, and we employed a plethora of electronic search databases including PubMed/Medline, Google Scholar, Scopus and other relevant literature sources. Inclusion criteria were studies on MSUs in remote African communities, while exclusion criteria involved non- African or urban-focused studies. This review highlights that the current literature depicts that application of MSUs bring a positive impact in providing timely and quality surgical care to remote African communities. Frequent interventions, such as minor surgeries, obstetric procedures, and major trauma control, have been performed on MSUs. In settings with shortages of human resources and clinical equipments, these units have improved patient outcomes, reduced healthcare disparities, and increased access to emergency surgical care. While challenges such as financial constraints and surgical sustainability have been noted, the need for interdisciplinary collaboration and the advantages of MSU deployment often help mitigate these obstacles. A lack of surgical care for individuals living in remote African domiciles may be addressed via MSU application. Through delivering fundamental surgical services directly to underserved populations, MSUs may potentially prevent disabilities, save countless lives, and enhance overall health outcomes in African remote communities. To guarantee the long-term feasibility and sustainability of MSU programs in Africa, however, more funding must be allocated to infrastructure, supplies, and relevant education.

Introduction: Since the advent of highly active antiretroviral therapy (HAART), morbidity and mortality rates associated with human immunodeficiency virus (HIV) have significantly decreased leading to prolonged life span of Individuals living with HIV due to the effectiveness of antiretroviral therapy. However, this prolonged lifespan alone does not fully account for the increased incidence of cardiometabolic complications. These complications result from a complex interplay of factors such as chronic inflammation, immune activation, ART‐related metabolic effects, and lifestyle changes. which contribute to elevated morbidity and mortality rates, therefore requiring a deeper understanding and setting effective management strategies. This review aims at providing insights and a nuanced understanding of the relationship between HIV and cardiometabolic disorders, explore their clinical implications and adapt optimal management strategies to address the multifaceted challenges at the intersection of HIV and cardiometabolic health, ultimately enhancing patient outcomes and quality of life.Methods: Data retrieval was conducted using a predetermined search strategy from medical journals that were published in bibliographical databases like PubMed, Science Direct and Embase. This review systematically considered and synthesized current literature on the association between cardiometabolic challenges and HIV.Results: This review provides a detailed exploration of the interrelationship between HIV and cardiometabolic challenges, with an emphasis on insights, impact, and best practices for optimal management. It underscores the high risk of cardiovascular disease, insulin resistance, dyslipidemia, and lipodystrophy in people living with HIV. Recommendations include evidence‐based approaches such as routine cardiometabolic risk. Prevention, screening, management, lifestyle interventions (diet and exercise), and optimizing ART regimens to reduce the negative health outcomes experienced by people living with HIV and to direct clinical practice. To reduce health issues, enhance clinical results, and improve the long‐term quality of life for people living with HIV, it is important to early identify cardiovascular risk factors and to follow customized prevention and management methods.Conclusion: This review shows that early detection through regular screening is pivotal through collaboration between healthcare providers, researchers, and policymakers which will allow for timely interventions and drive innovation and address evolving challenges to enhancing the quality of life for individuals living with HIV. Continuing to do research and advocacy efforts, will not only advance knowledge but also optimize the long‐term health outcomes for people living with HIV.

Background: Antimicrobial resistance (AMR) is one of the most urgent global public health threats, especially in low‐ and middle‐income countries. In 2019, bacterial AMR was estimated to have directly caused approximately 1.27 million deaths and to have been associated with 4.95 million deaths worldwide. Rapid identification of resistant infections is important, yet established diagnostics are very slow. In recent years, artificial intelligence (AI) has revolutionized microbiology and infectious disease diagnostics. This review explores the space of AI‐enabled diagnostics for AMR detection and characterization. Methods: This literature review was conducted from January to September 2026 using PubMed/MEDLINE, Google Scholar, and other electronic databases with keywords including “AI,” “AMR,” “deep learning,” “genomic diagnostics,” and “point‐of‐care (POC) testing.” Following screening and full‐text assessment, 67 Peer‐reviewed articles and systematic reviews were included to support the synthesis presented in the manuscript, while non‐peer‐reviewed articles and studies lacking direct AI relevance were excluded. Titles and abstracts were screened before full‐text review. Results: AI‐enhanced diagnostics were reported to shorten turnaround time for AMR detection with promising but heterogeneous predictive performance; for example, pooled estimates across antimicrobial stewardship applications indicate an area under the curve of approximately 0.72. They also support improving antimicrobial stewardship and enable early therapeutic optimization in laboratory and POC settings, enabling real‐time clinical decision‐making. Despite these achievements, evidence for direct improvements in patient outcomes and routine bedside effectiveness remains limited. Conclusion: AI‐driven diagnostic tools represent a promising strategy to bridge laboratory innovation and bedside application in combating AMR. The tools have the capacity to improve patient outcomes and enhance antimicrobial stewardship as they can accurately detect resistance patterns and support real‐time clinical decisions. However, long‐term sustainability, long‐term success, and global impact can be achieved by continued validation, regulatory alignment, and equitable implementation across diverse healthcare settings.